<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ro">
	<id>https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=REGULUS_THERAPEUTICS_INC</id>
	<title>REGULUS THERAPEUTICS INC - Revizia istoricului</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=REGULUS_THERAPEUTICS_INC"/>
	<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=REGULUS_THERAPEUTICS_INC&amp;action=history"/>
	<updated>2026-04-06T20:50:06Z</updated>
	<subtitle>Istoricul versiunilor pentru această pagină din wiki</subtitle>
	<generator>MediaWiki 1.39.2</generator>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=REGULUS_THERAPEUTICS_INC&amp;diff=438331&amp;oldid=prev</id>
		<title>Admin: Pagină nouă: Pagina dedicata companiei REGULUS THERAPEUTICS INC listata cu simbolul US.RGLS  ==Descriere companie== Regulus Therapeutics Inc. (http://www.regulusrx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multi...</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=REGULUS_THERAPEUTICS_INC&amp;diff=438331&amp;oldid=prev"/>
		<updated>2024-09-18T18:25:16Z</updated>

		<summary type="html">&lt;p&gt;Pagină nouă: Pagina dedicata companiei REGULUS THERAPEUTICS INC listata cu simbolul US.RGLS  ==Descriere companie== Regulus Therapeutics Inc. (http://www.regulusrx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multi...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Pagină nouă&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Pagina dedicata companiei REGULUS THERAPEUTICS INC listata cu simbolul US.RGLS&lt;br /&gt;
&lt;br /&gt;
==Descriere companie==&lt;br /&gt;
Regulus Therapeutics Inc. (http://www.regulusrx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.&lt;br /&gt;
&lt;br /&gt;
==Grafic actiuni companie==&lt;br /&gt;
&amp;lt;iframe key=&amp;quot;tradeville&amp;quot; path=&amp;quot;graficSimbol/US.RGLS&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Ultimele stiri despre REGULUS THERAPEUTICS INC (US.RGLS)==&lt;br /&gt;
&amp;lt;dynamicpagelist&amp;gt;&lt;br /&gt;
category=US.RGLS&lt;br /&gt;
count=10&lt;br /&gt;
order=descending&lt;br /&gt;
addfirstcategorydate=false&lt;br /&gt;
&amp;lt;/dynamicpagelist&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Categorie:US.RGLS]][[Categorie:Stiri despre companii]]&lt;/div&gt;</summary>
		<author><name>Admin</name></author>
	</entry>
</feed>